This tracker started as a scan of ClinicalTrials.gov, but it reads better once a few of the entries are tied to the strongest direct sources available instead of left as a bare list of NCT numbers.
CYB003: Cybin's Pivotal Program Is Actually Taking Shape
NCT06564818 is the cleanest example of a trial that benefits from one company-side anchor in addition to the registry. ClinicalTrials.gov lists it as a phase 3, recruiting, randomized, double-blind, placebo-controlled study of CYB003 as an adjunctive treatment for major depressive disorder, with 220 participants and estimated primary completion in August 2026.
That is the live operational frame. Cybin's own PARADIGM phase 3 release adds the broader program context, describing APPROACH and EMBRACE as two 12-week randomized, placebo-controlled studies plus a long-term extension study called EXTEND.
That pairing makes the CYB003 item feel less like a disconnected registry entry and more like what it is, a real company-run late-stage program that is already in motion.
MDMA for Therapist Trainees: Still Registry-Led, but More Specific Than It Sounds
NCT07102576 remains a registry-led item, and that is fine. The study is recruiting, has estimated enrollment of 30, and is being run through The Parsons Research Center for Psychedelic Healing in New York, with Rachel Yehuda listed as sponsor-investigator and the Icahn School of Medicine at Mount Sinai named as her affiliation.
The trial is unusual because it is not a patient-efficacy study in the usual sense. It is a phase 1, open-label study of MDMA-assisted therapy for mental healthcare providers who are training to become MDMA-assisted therapists. According to the registry, participants complete a preparatory session, one experimental MDMA session, an integration session the following day, and follow-up about one month later. The intervention section lists an initial 120 mg dose of MDMA HCl with an optional 40 mg supplemental dose.
So the core thing to watch here is not whether MDMA works for PTSD again. It is whether the field keeps formalizing therapist-training models that include direct experiential exposure under research conditions.
Severe Alcohol Use Disorder: Brigham's Study Looks More Serious With the Protocol in View
NCT07296094 is a phase 2, not yet recruiting Brigham and Women's Hospital study in severe alcohol use disorder, with estimated enrollment of 36 and a projected May 2026 start. The current registry entry describes a double-blind randomized design comparing lower-dose and higher-dose psilocybin, with two dosing sessions four weeks apart, structured psychotherapy, peer recovery support, and follow-up measures that extend well past the acute dosing window.
The linked protocol paper helps explain why this one stands out. It frames the project as a dedicated phase 2 study in severe alcohol use disorder rather than just another generic addiction pilot, and it makes clear that the team is trying to connect clinical drinking outcomes to neurocognitive and neuroimaging measures.
The registry should still be treated as the live source for recruitment status and current design specifics. But the paper gives the item more depth than a single NCT link can carry on its own.
CAMH and OCD: Small, Focused, and Still Worth Watching
NCT06299319 is a recruiting phase 1 trial from the Centre for Addiction and Mental Health in Toronto. The registry says it is enrolling 10 participants with treatment-resistant OCD in an open-label design, with two 25 mg psilocybin sessions given two weeks apart under supportive conditions.
That is still a small feasibility study, not a late-stage efficacy program. But OCD remains an important indication to watch precisely because the evidence base is thinner than it is in depression, and this study is explicit about testing safety, feasibility, and early clinical effects rather than pretending the question is already settled.
Brazil's Psilocybin Plus Fluoxetine Trial Gets at a Real Clinical Problem
NCT06898606 is one of the more interesting registry entries in the set because it asks a question that matters immediately in practice. The study is recruiting, has estimated enrollment of 24, and randomizes adults with refractory depression to a single psychedelic-assisted session using 3 g of standardized Psilocybe mushrooms plus either fluoxetine 20 mg/day or matching placebo.
The design matters here. Fluoxetine starts two weeks before the psychedelic session and continues two weeks after, which lets the team ask whether concurrent SSRI treatment changes antidepressant response, acute psychedelic effects, or tolerability. That is a cleaner and more useful framing than the vaguer claim that researchers are simply mixing antidepressants and psychedelics to see what happens.
Taken together, these five entries show a field that is still heavily registry-driven, but no longer as one-note as it can seem from the outside. Late-stage company programs, therapist-training studies, addiction protocols, OCD pilots, and antidepressant-interaction questions are all moving at once. The page is stronger when those differences are made explicit and tied to the best direct sources available for each leg.